Zuzie, good post. I've added some comments:
1. Given the small size of Ariad with only 307 employees and a few products in development/pipeline, why there are so many directors (=9) on the the board and so many VPs (=22) on executive management team? It's very often that by having too many people in management, it's very difficult for getting the works done because of too many opinion/idea/commands flying around. Don't you question HB's leadership & skills in building and maintaining a highly efficient and effective management team?
>>>>>>>
(I think they are down to 180 employees. The 22 VP's is absolutely ridiculous for a company with a last resort fourth round drug. Celegene at 20 times the size has 14 VP's)
2. With a bunch of new hires early this years (Huge Cole, Timothy Maines, Yan Moore, Piet Vervaet, ...) how come all of this not translated into revenue increase Q-by-Q and no new product development announcement? And if you check Ariad's hiring website, there are still 23 open positions (mostly management). What's the point of continue hiring a bunch of people when there isn't much going on? Given this, don't you question HB's ability in managing the company?
>>>>>
(For an early stage biotech, those four new hires, Just after the convertible bond offering I might add, was pure Harvey Berger. Insanely not right, borderline unethical.)
3. What the PR people at Ariad are doing lately? Isn't that they're supposed to to go out drumming up the world with all the latest development at Ariad? So far, we're seeing is they're getting paid for doing nothing.
>>>>
(There is really not much for them to do. A recent tweet confirms they are going to miss their Q3 2014 sales number due to overstated IMS sales number last month. What the PR department needs to do is prepare the existing shareholders for the dilution in view for late 2015.)
$6 for a long time unless Berger pursues other interests.
